REUTERS: Moderna Inc and Merck & Co on Tuesday told a US Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.
Gerberding and a representative from Moderna did not comment on the price they have in mind for their vaccines at the hearing, which focused on efforts to develop a safe, effective and widely accessible vaccine against COVID-19, which has claimed 600,000 lives globally. "We didn't access federal funding solely for the reason that we wanted to move the vaccine faster to the clinic," Young said.
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше: